SCHEMBL22019783

SCHEMBL22019783

Cc1c2c(nc(C(F)(F)F)c1C1CC1)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NLRP3 Q96P20 1/20 0.38
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 2/20 0.33
TP53 P04637 1/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPK1 P28482 3/20 0.32
HSD17B10 Q99714 2/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
MEN1 O00255 1/20 0.31
ACHE P22303 1/20 0.31
KMT2A Q03164 1/20 0.31
BPTF Q12830 1/20 0.31
EEF2K O00418 1/20 0.30
NOS3 P29474 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24978541 0.83 SMN1; SMN2 (0.39) SMN1; SMN2L3MBTL1NLRP3CYP1A2CYP2C19
SCHEMBL22019979 0.81 ACHE (0.46) SMN1; SMN2L3MBTL1NLRP3MAPK1MEN1
SCHEMBL30162299 0.81 ACHE (0.46) SMN1; SMN2L3MBTL1NLRP3MAPK1MEN1
SCHEMBL22020383 0.81 NLRP3 (0.44) SMN1; SMN2L3MBTL1NLRP3CYP1A2CYP2C19
SCHEMBL22019708 0.80 SMN1; SMN2 (0.46) SMN1; SMN2L3MBTL1CYP1A2CYP2C19LMNA
SCHEMBL22019726 0.78 KDM4E (0.39) SMN1; SMN2L3MBTL1CYP1A2KDM4EMAPK1
SCHEMBL22020067 0.77 KDM4E (0.36) NLRP3CYP1A2KDM4EMAPK1ALDH1A1
SCHEMBL21963408 0.76 NLRP3 (0.52) SMN1; SMN2L3MBTL1NLRP3CYP1A2TP53
SCHEMBL22020718 0.76 SMN1; SMN2 (0.43) SMN1; SMN2L3MBTL1CYP1A2CYP2C19LMNA
SCHEMBL22020719 0.73 SMN1; SMN2 (0.41) SMN1; SMN2L3MBTL1CYP1A2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102096-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed